Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lilly GMP Strategy: Avoid Consent Degree With Open Communication At FDA

Sep 30 2002

• By The Pink Sheet

Related Content

Lilly Cialis Using Alternate Manufacturing Facilities For 2nd Half 2003 Launch

Jul 22 2002

Schering NDAs Are Clear For Review Under FDA Consent Decree

May 27 2002

Lilly Zyprexa IM "Approvable"; GMP Consultants Hired In Wake Of Inspections

Apr 16 2001

Lilly, FDA Discussing Insulin GMP Upgrades To Avoid Supply Restrictions

Jan 28 2002

Lilly Chief Compliance Officer Queisser Will Communicate Corporate GMPs

Sep 09 2002

Zyprexa IM Manufacturing Issues To Be Discussed By FDA, Lilly March 15

Mar 12 2001

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window